Rocket Pharmaceuticals Bolsa (NASDAQ: RCKT)

Rocket Pharmaceuticals (NASDAQ:RCKT) Bolsa

ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Descubre qué acciones sobrevendidas del sector salud tienen un RSI por debajo de 30 y podrían estar infravaloradas.

3 acciones estadounidenses de atención médica que podrían despegar este mes

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals Inc

ROCK TECH LINTHIUM INC by Rock Tech Lithium Inc.

Rock Tech Lithium Inc

<p><a href="https://www.wsj.com/tech/ai/softbank-openai-a3dc57b4">https://www.wsj.com/tech/ai/softbank-openai-a3dc57b4</a></p>


General

MSFT

'SoftBank and Open AI's $500 Billion AI Project Struggles to Get Off Ground'- WSJ

<p>Set forth below are preliminary estimates of selected unaudited financial information and other information for the three months ended June 30, 2025, and actual unaudited financial results for the three months ended June 30, 2024. We have provided ranges of certain preliminary results below because our closing procedures for our fiscal quarter ended June 30, 2025 are not yet complete. These ranges are based on the information available to us as of the date of this press release. Our final results remain subject to customary closing procedures or subsequent events, however we do not expect our final results to materially differ from the preliminary results shown below. These preliminary estimates are forward-looking statements. Our unaudited financial results as of the three months ended June 30, 2025 are not yet finalized. During the course of the preparation of our unaudited financial statements and the notes thereto by management, additional items that require adjustments to the preliminary results presented below may be identified.</p>
<p>The preliminary results provided below do not represent a comprehensive statement of our financial results and should not be viewed as a substitute for the financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP). In addition, the preliminary results for the three months ended June 30, 2025 are not necessarily indicative of the results to be achieved in any future period.</p>
<p>&nbsp;</p>
<p>The estimates of Karman&#39;s revenue, gross profit, pretax income, net income, funded backlog and adjusted EBITDA, as of June 30, 2025 are preliminary, have not been audited, do not present all information necessary for an understanding of Karman&#39;s financial condition as of June 30, 2025, and are subject to change upon completion of Karman&#39;s financial statement closing procedures. The preliminary financial data included in the above has been prepared by, and is the responsibility of, Karman&#39;s management. Karman&#39;s independent registered public accounting firm has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Karman&#39;s independent registered public accounting firm does not express an opinion or any other form of assurance with respect thereto.</p>
<p>For the three months ended June 30, 2025, we expect revenue to be between $114.50 million and $115.00 million, representing an estimated increase of approximately 34.6% and 35.2%, compared to revenue of $85.04 million for the three months ended June 30, 2024.</p>
<p>For the three months ended June 30, 2025, we expect total gross profit to be between $46.70 million and $47.00 million, compared to total gross profit of $34.59 million for the three months ended June 30, 2024</p>
<p>For the three months ended June 30, 2025, we expect income before provision for income taxes to be between $8.31 million and $8.40 million, compared to income before provision for income taxes of $4.92 million for the three months ended June 30, 2024.</p>
<p>For the three months ended June 30, 2025, we expect net income to be between $6.17 million and $6.20 million, compared to net income of $4.60 million for the three months ended June 30, 2024.</p>
<p>For the three months ended June 30, 2025, net income margin is expected to be 5.4%, compared to net income margin of 5.4% for the three months ended June 30, 2024.</p>
<p>For the three months ended June 30, 2025, we expect funded backlog to be between $712.00 million and $715.00 million, representing an estimated increase of approximately 34.8% and 35.4%, compared to funded backlog of $528.01 million for the three months ended June 30, 2024.</p>
<p>For the three months ended June 30, 2025, Adjusted EBITDA is expected to be between $34.85 million and $35.15 million, compared to Adjusted EBITDA of $27.42 million for the three months ended June 30, 2024. For the three months ended June 30, 2025, Adjusted EBITDA margin is expected to be between 30.4% and 30.6%, compared to Adjusted EBITDA margin of 32.2% for the three months ended June 30, 2024.</p>


KRMN

Karman Space & Defense Releases Preliminary Q2 Fiscal Year 2025 Financial Results; Q2 Revenue Expected Between $114.50M-$115.00M, Up 34.6%-35.2% YoY

<p>AutoCanada Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACQ#TSX">ACQ</a>), a multi-location North American automobile dealership group, today announced that it has selected CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>), the fastest-growing automotive shopping site in Canada1, as its preferred partner in Canada. Through this long-term relationship, AutoCanada will have access to the power and reach of CarGurus&#39; leading listings marketplace, advanced digital marketing and retail solutions, and market intelligence powered by proprietary data and predictive insights.</p>
<p>AutoCanada dealers will benefit from CarGurus&#39; solutions that help maximize visibility, connect with ready-to-buy shoppers, and make more data-informed decisions on vehicle pricing, inventory management, and digital advertising. The group&#39;s 64 franchised dealerships and three used car dealerships in Canada will also have ongoing access to strategic consultation from CarGurus&#39; in-person dealer engagement team, helping them navigate shifting market dynamics and consumer behavior.</p>


Global

CARG

CarGurus Named Preferred Partner By AutoCanada To Enhance Digital Strategy Across Dealerships

<h3>Gainers</h3>
<ul>
<li><strong>Genius Group</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares moved upwards by 7.5% to $1.29 during Monday's after-market session. The market value of their outstanding shares is at $118.9 million. </li>
<li><strong>Children's Place</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) shares moved upwards by 4.98% to $5.48. The company's market cap stands at $114.1 million. </li>
<li><strong>Kaival Brands Innovations</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) shares moved upwards by 4.16% to $0.5. The market value of their outstanding shares is at $5.8 million. </li>
<li><strong>Brilliant Earth Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) shares rose 4.02% to $1.55. The market value of their outstanding shares is at $20.9 million. </li>
<li><strong>SharpLink Gaming</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock rose 3.98% to $26.25. The market value of their outstanding shares is at $2.7 billion. </li>
<li><strong>TCTM Kids IT Education</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) shares rose 3.33% to $1.86. The company's market cap stands at $17.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Lindblad Expeditions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) stock decreased by 8.0% to $11.36 during Monday's after-market session. The company's market cap stands at $681.1 million. </li>
<li><strong>Tuniu</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOUR#NASDAQ">TOUR</a>) stock fell 3.79% to $0.84. The company's market cap stands at $99.8 million. </li>
<li><strong>Newton Golf</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTG#NASDAQ">NWTG</a>) stock fell 3.66% to $1.58. The market value of their outstanding shares is at $6.7 million. </li>
<li><strong>Golden Heaven Group Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares fell 3.4% to $0.68. The company's market cap stands at $34.6 million. </li>
<li><strong>Perfect Moment</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#AMEX">PMNT</a>) stock fell 3.34% to $0.35. </li>
<li><strong>Autozi Internet Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) shares decreased by 3.32% to $0.26. The company's market cap stands at $29.4 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

BRLT

GDHG

KAVL

LIND

NWTG

PLCE

PMNT

SBET

TOUR

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Medpace Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares moved upwards by 48.9% to $460.02 during Monday's after-market session. The market value of their outstanding shares is at $8.9 billion. The company's, Q2 earnings came out today. </li>
<li><strong>Genelux</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock increased by 7.65% to $3.78. The company's market cap stands at $125.7 million. </li>
<li><strong>Rafael Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) stock rose 7.54% to $2.28. The market value of their outstanding shares is at $72.3 million. </li>
<li><strong>Cyclacel Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 7.37% to $12.52. The market value of their outstanding shares is at $20.7 million. </li>
<li><strong>Ovid Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) stock rose 7.36% to $0.65. The company's market cap stands at $39.1 million. </li>
<li><strong>Charles River</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares increased by 6.81% to $160.0. The company's market cap stands at $7.8 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Healthcare Triangle</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 9.8% to $0.02 during Monday's after-market session. The market value of their outstanding shares is at $7.8 million. </li>
<li><strong>Barinthus Biotherapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares fell 9.65% to $1.78. The market value of their outstanding shares is at $60.4 million. </li>
<li><strong>TNF Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 9.51% to $0.12. The company's market cap stands at $1.2 million. </li>
<li><strong>DIH Holding US</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) shares declined by 7.07% to $0.27. The market value of their outstanding shares is at $11.7 million. </li>
<li><strong>Neuraxis</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#AMEX">NRXS</a>) stock fell 6.6% to $2.55. The company's market cap stands at $24.9 million. </li>
<li><strong>OneMedNet</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock fell 6.11% to $0.54. The market value of their outstanding shares is at $25.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BRNS

CYCC

DHAI

GNLX

HCTI

MEDP

NRXS

ONMD

OVID

TNFA

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Professional Diversity</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares moved upwards by 13.9% to $2.9 during Monday's after-market session. The company's market cap stands at $6.0 million. </li>
<li><strong>Dragonfly Energy Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares moved upwards by 9.94% to $0.29. The company's market cap stands at $1.5 million. </li>
<li><strong>NeoVolta</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) shares rose 9.61% to $4.9. The company's market cap stands at $155.6 million. </li>
<li><strong>Grab Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) shares rose 9.34% to $5.85. The company's market cap stands at $21.5 billion. </li>
<li><strong>Linkers Industries</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKS#NASDAQ">LNKS</a>) stock rose 7.05% to $0.59. The market value of their outstanding shares is at $7.4 million. </li>
<li><strong>Euro Tech Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLWT#NASDAQ">CLWT</a>) shares rose 6.95% to $1.23. The market value of their outstanding shares is at $9.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Lichen International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) stock declined by 5.5% to $4.16 during Monday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li><strong>Roma Green Finance</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROMA#NASDAQ">ROMA</a>) shares declined by 5.24% to $3.35. The company's market cap stands at $52.1 million. </li>
<li><strong>ATIF Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) stock decreased by 5.14% to $0.47. The market value of their outstanding shares is at $9.1 million. </li>
<li><strong>Safe Pro Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) shares decreased by 5.09% to $3.55. The company's market cap stands at $60.6 million. </li>
<li><strong>WF Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) stock decreased by 4.24% to $1.13. The market value of their outstanding shares is at $28.7 million. </li>
<li><strong>Spire Global</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) shares fell 4.23% to $11.55. The market value of their outstanding shares is at $380.9 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CLWT

DFLI

GRAB

IPDN

LICN

LNKS

NEOV

ROMA

SPAI

SPIR

ZBAI

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Auddia</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) stock moved upwards by 6.5% to $4.39 during Monday's after-market session. The market value of their outstanding shares is at $2.6 million. </li>
<li><strong>CVD Equipment</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) shares moved upwards by 6.32% to $3.7. The company's market cap stands at $25.3 million. </li>
<li><strong>Mobilicom</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOB#NASDAQ">MOB</a>) shares rose 4.81% to $3.7. The company's market cap stands at $30.4 million. </li>
<li><strong>Indie Semiconductor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) shares moved upwards by 4.76% to $4.62. The company's market cap stands at $912.0 million. </li>
<li><strong>MMTEC</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares increased by 4.52% to $0.92. The company's market cap stands at $22.1 million. </li>
<li><strong>SEALSQ</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares rose 3.79% to $3.56. The market value of their outstanding shares is at $435.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>ReAlpha Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) shares declined by 50.9% to $0.42 during Monday's after-market session. The market value of their outstanding shares is at $10.6 million. </li>
<li><strong>Agilysys</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) shares declined by 10.22% to $105.0. The market value of their outstanding shares is at $3.2 billion. The company's, Q1 earnings came out today. </li>
<li><strong>Mobix Labs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares declined by 5.94% to $1.11. The market value of their outstanding shares is at $46.0 million. </li>
<li><strong>Robot Consulting Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAWR#NASDAQ">LAWR</a>) shares decreased by 3.89% to $3.21. The market value of their outstanding shares is at $170.9 million. </li>
<li><strong>Cambium Networks</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares declined by 3.68% to $1.31. The market value of their outstanding shares is at $27.0 million. </li>
<li><strong>KVH Industries</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>) shares declined by 3.58% to $5.12. The market value of their outstanding shares is at $104.8 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AGYS

AIRE

AUUD

CMBM

INDI

KVHI

LAES

LAWR

MOBX

12 Information Technology Stocks Moving In Monday's After-Market Session

Management

Ashland Names William C. Whitaker Senior Vice President And Chief Financial Officer, Effective July 18, 2025

UYSCR

Trading Halt: Halt status updated at 5:05:00 PM ET: Quotation Resumption: News and Resumption Times

WIIM

AIRE stock has given up its prior loss. ReAlpha Tech shares were trading lower after the company announced a $5 million registered direct offering.

Earnings

Earnings Beats

SMBK

SmartFinancial Q2 Adj. EPS $0.69 Beats $0.64 Estimate, Sales $49.24M Beat $48.49M Estimate

<p>In the latest quarter, 13 analysts provided ratings for Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Lyft, presenting an average target of $18.08, a high estimate of $28.00, and a low estimate of $14.00. This upward trend is apparent, with the current average reflecting a 3.08% increase from the previous average price target of $17.54.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753131703_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Lyft by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nikhil Devnani</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Chad Larkin</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$14.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Hold</td>
<td>$14.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lyft. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lyft compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Lyft's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Lyft's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LYFT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Lyft analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Lyft</h2>
<p>Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.</p>
<h3>Lyft's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Lyft's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>13.54%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Lyft's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>0.18%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Lyft's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.32%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Lyft's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.05%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Lyft's debt-to-equity ratio surpasses industry norms, standing at <strong>1.41</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

LYFT

What 13 Analyst Ratings Have To Say About Lyft

<p>Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $88.62, with a high estimate of $110.00 and a low estimate of $70.00. This upward trend is apparent, with the current average reflecting a 4.26% increase from the previous average price target of $85.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753131693_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A clear picture of Qorvo's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Announces</td>
<td>Buy</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Qorvo. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Qorvo compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Qorvo's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Qorvo's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/QRVO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Qorvo analyst ratings.</strong></a></p>
<h2>Delving into Qorvo's Background</h2>
<p>Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.</p>
<h3>Qorvo: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Qorvo's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-7.6%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Qorvo's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>3.61%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Qorvo's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>0.93%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Qorvo's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.53%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Qorvo's debt-to-equity ratio surpasses industry norms, standing at <strong>0.46</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


QRVO

Where Qorvo Stands With Analysts

<p>Ratings for Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) were provided by 28 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">14</td>
<td align="right">13</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $102.79, a high estimate of $120.00, and a low estimate of $82.00. This current average reflects an increase of 11.59% from the previous average price target of $92.11. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753131685_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Uber Technologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Nikhil Devnani</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$109.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$84.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Uber Technologies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Uber Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Uber Technologies's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Uber Technologies's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UBER/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Uber Technologies analyst ratings.</strong></a></p>
<h2>Discovering Uber Technologies: A Closer Look</h2>
<p>Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing (eVTOL) technology. Uber operates in over 70 countries, with over 170 million users who order rides or food at least once a month.</p>
<h3>Unraveling the Financial Story of Uber Technologies</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Uber Technologies showcased positive performance, achieving a revenue growth rate of <strong>13.84%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Uber Technologies's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>15.4%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Uber Technologies's ROE excels beyond industry benchmarks, reaching <strong>8.16%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Uber Technologies's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>3.41%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Uber Technologies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.51</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


UBER

Analyst Expectations For Uber Technologies's Future

<p>Analysts' ratings for Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Amgen and provided 12-month price targets. The average target is $311.25, accompanied by a high estimate of $328.00 and a low estimate of $280.00. This current average reflects an increase of 1.1% from the previous average price target of $307.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753131674_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Amgen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$326.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$328.00</td>
<td>$328.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$305.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Neutral</td>
<td>$288.00</td>
<td>-</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$328.00</td>
<td>$329.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$315.00</td>
<td>$319.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$320.00</td>
<td>$324.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amgen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Amgen compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Amgen's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Amgen's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AMGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Amgen analyst ratings.</strong></a></p>
<h2>Get to Know Amgen Better</h2>
<p>Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.</p>
<h3>Amgen's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Amgen's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>9.43%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>21.23%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>28.63%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Amgen's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.91%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Amgen's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>9.24</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AMGN

What Analysts Are Saying About Amgen Stock

<p>Looking into the current session, <strong>Agree Realty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>)</strong> shares are trading at $71.32, after a <strong>0.43%</strong> drop. Over the past month, the stock fell by <strong>4.78%</strong>, but over the past year, it actually spiked by <strong>6.94%</strong>. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1753131669_0.png" alt="Past Year Chart" /></p>

<h3>Agree Realty P/E Compared to Competitors</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Agree Realty has a lower P/E than the aggregate P/E of <strong>59.06</strong> of the Retail REITs industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1753131669_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

A Look Into Agree Realty Inc's Price Over Earnings

<p>In the last three months, 4 analysts have published ratings on Veralto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Veralto, revealing an average target of $107.5, a high estimate of $116.00, and a low estimate of $104.00. Witnessing a positive shift, the current average has risen by 3.86% from the previous average price target of $103.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753131654_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Veralto's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$116.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$104.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$104.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Veralto. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Veralto compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Veralto's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Veralto's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VLTO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Veralto analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Veralto</h2>
<p>Veralto is a diversified industrial firm organized into two segments, water quality as well as product quality and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.2 billion in revenue in 2024.</p>
<h3>Financial Insights: Veralto</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Veralto's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>6.9%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Veralto's net margin excels beyond industry benchmarks, reaching <strong>16.89%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>10.37%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Veralto's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.45%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Veralto's debt-to-equity ratio is below the industry average at <strong>1.14</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VLTO

The Analyst Verdict: Veralto In The Eyes Of 4 Experts

<p>Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Crane and provided 12-month price targets. The average target is $195.0, accompanied by a high estimate of $226.00 and a low estimate of $150.00. This current average reflects an increase of 12.18% from the previous average price target of $173.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753131644_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive Crane is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$189.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Matt Summerville</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Scott Deuschle</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$150.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$157.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Crane. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Crane compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Crane's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Crane's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Crane analyst ratings.</strong></a></p>
<h2>Get to Know Crane Better</h2>
<p>Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.</p>
<h3>A Deep Dive into Crane's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Crane's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>9.29%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>19.21%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>6.31%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Crane's ROA excels beyond industry benchmarks, reaching <strong>4.07%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.15</strong>, Crane adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Crane Stock

<p>H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) has outperformed the market over the past 5 years by 16.1% on an annualized basis producing an average annual return of 30.5%. Currently, H&amp;R Block has a market capitalization of $7.42 billion. </p>
<p><strong>Buying $100 In HRB:</strong> If an investor had bought $100 of HRB stock 5 years ago, it would be worth <strong>$381.10</strong> today based on a price of $55.45 for HRB at the time of writing.</p>
<h3>H&amp;R Block's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753131623_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning H&R Block Stock In The Last 5 Years

UYSCU

Trading Halt: Halt status updated at 5:00:00 PM ET: Quotation Resumption: News and Resumption Times

Press Releases

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for Investors - Contact Levi & Korsinsky

Legal

DEADLINE ALERT for VSTS, RCKT, TEM, and DDD: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RCKT

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact The Gross Law Firm

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

SHAREHOLDER ALERT: Berger Montague Reminds Rocket Pharmaceuticals (NASDAQ: RCKT) Investors of Class Action Lawsuit Deadline

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm

Comments

Rocket Pharmaceuticals

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL